Drug fail­ure hurts Eli Lilly

Daily Freeman (Kingston, NY) - - BUSINESS -

In­vestors ham­mered stock in In­di­anapo­lis drug­maker Eli Lilly Wed­nes­day af­ter one of the com­pany’s po­ten­tial Alzheimer’s drugs failed a clin­i­cal trial.

The com­pany said solanezumab did not slow pa­tients’ men­tal de­cline com­pared to a placebo. The re­sults dashed hopes that Eli Lilly re­searchers had fi­nally found a drug that does more to help those suf­fer­ing from the fa­tal, mind-rob­bing dis­ease. Alzheimer’s is a deadly, de­gen­er­a­tive dis­ease that im­pairs mem­ory and thought. With more than 5 mil­lion peo­ple in the United States af­flicted, it’s the most com­mon form of de­men­tia. It’s also the sixth-lead­ing cause of death in the U.S. and the only one with no pre­ven­tion, cure or even a way to slow its pro­gres­sion, ac­cord­ing to the Alzheimer’s As­so­ci­a­tion.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.